文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

作者信息

Jia Bei, Wang Liru, Claxton David F, Ehmann W Christopher, Rybka Witold B, Mineishi Shin, Rizvi Syed, Shike Hiroko, Bayerl Michael, Schell Todd D, Hohl Raymond J, Zheng Hong

机构信息

Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA, 17033, USA.

Fu Xing Hospital, Capital Medical University, Beijing, 100038, China.

出版信息

Blood Cancer J. 2018 Mar 21;8(3):34. doi: 10.1038/s41408-018-0069-4.

DOI:10.1038/s41408-018-0069-4
PMID:29563517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5862839/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bb/5862839/9c2f808c29fe/41408_2018_69_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bb/5862839/7813f05c6079/41408_2018_69_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bb/5862839/9c2f808c29fe/41408_2018_69_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bb/5862839/7813f05c6079/41408_2018_69_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99bb/5862839/9c2f808c29fe/41408_2018_69_Fig2_HTML.jpg

相似文献

[1]
Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Blood Cancer J. 2018-3-21

[2]
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Cancer. 2018-11-30

[3]
A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia.

J Leukoc Biol. 2019-5-28

[4]
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

J Hematol Oncol. 2015-7-30

[5]
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

JCI Insight. 2018-11-2

[6]
Lactate acid promotes PD-1 Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia.

Int Immunopharmacol. 2024-3-30

[7]
IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.

Mol Ther. 2005-1

[8]
Clinical implications of aberrant PD-1 expression for acute leukemia prognosis.

Eur J Med Res. 2023-9-27

[9]
Increased PD-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival.

Ann Clin Biochem. 2024-3

[10]
Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.

Cancer Biomark. 2018

引用本文的文献

[1]
The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response.

Front Immunol. 2025-8-11

[2]
CAR-T cell therapy for cancer: current challenges and future directions.

Signal Transduct Target Ther. 2025-7-4

[3]
Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients.

Leuk Res Rep. 2025-5-9

[4]
Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.

Cancer Immunol Immunother. 2025-2-25

[5]
Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis.

Heliyon. 2024-10-25

[6]
Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche.

Explor Target Antitumor Ther. 2024

[7]
Immune-dysregulation harnessing in myeloid neoplasms.

Cancer Med. 2024-9

[8]
CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.

Inflamm Res. 2024-3

[9]
Progress of research on PD-1/PD-L1 in leukemia.

Front Immunol. 2023

[10]
Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies.

Chin J Cancer Res. 2023-6-30

本文引用的文献

[1]
Recent developments in immunotherapy of acute myeloid leukemia.

J Hematol Oncol. 2017-7-25

[2]
The bone marrow microenvironment - Home of the leukemic blasts.

Blood Rev. 2017-3-12

[3]
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017-1-26

[4]
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.

Clin Cancer Res. 2016-1-13

[5]
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.

Blood Cancer J. 2015-7-31

[6]
Immune checkpoint blockade: a common denominator approach to cancer therapy.

Cancer Cell. 2015-4-13

[7]
Overcoming T cell exhaustion in infection and cancer.

Trends Immunol. 2015-4

[8]
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Leukemia. 2013-11-25

[9]
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Oncologist. 2012-1-30

[10]
PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.

Cancer Res. 2011-6-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索